Application of genetically engineered biopharmaceutical products in children with various JIA forms in the Karaganda region
The article presents the experience of using biopharmaceutical products for the treatment of children with juvenile idiopathic arthritis in the cardio-rheumatological department of the PSE “Children’s Hospital of Karaganda” for the period from January 1, 2013, to December 31, 2017. The study include...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
EDP Sciences
2024-01-01
|
| Series: | BIO Web of Conferences |
| Subjects: | |
| Online Access: | https://www.bio-conferences.org/articles/bioconf/pdf/2024/03/bioconf_aquaculture2024_03028.pdf |
| _version_ | 1797353033281044480 |
|---|---|
| author | Kenzhetaeva Tattigul Serikova Gulmira Alimshaikhina Kulzhazira Issayeva Aiman Sabiyeva Makpal Sarmankulova Gulmira |
| author_facet | Kenzhetaeva Tattigul Serikova Gulmira Alimshaikhina Kulzhazira Issayeva Aiman Sabiyeva Makpal Sarmankulova Gulmira |
| author_sort | Kenzhetaeva Tattigul |
| collection | DOAJ |
| description | The article presents the experience of using biopharmaceutical products for the treatment of children with juvenile idiopathic arthritis in the cardio-rheumatological department of the PSE “Children’s Hospital of Karaganda” for the period from January 1, 2013, to December 31, 2017. The study included 46 patients with JIA who were on genetically engineered biological therapy (girls 28-60.8%, boys 18-39.1%). Among all patients, 12 (26.1%) suffered from the oligoarticular variant of juvenile idiopathic arthritis with (JIA), 15 (32.6%) – from polyarticular seronegative variant (JIA), 14 (30.4%) – from systemic form (JIA), and 5 (10.9%) from other variants. Adalimumab was used in 24 patients (50.2%). Tocilizumab in 17 (30%) ones, 14 of which had a systemic variant of JIA. Infliximab was applied for 5 patients (10.8%). |
| first_indexed | 2024-03-08T13:24:22Z |
| format | Article |
| id | doaj.art-2f4c3ee2a1b44519af724f24456ecd1d |
| institution | Directory Open Access Journal |
| issn | 2117-4458 |
| language | English |
| last_indexed | 2024-03-08T13:24:22Z |
| publishDate | 2024-01-01 |
| publisher | EDP Sciences |
| record_format | Article |
| series | BIO Web of Conferences |
| spelling | doaj.art-2f4c3ee2a1b44519af724f24456ecd1d2024-01-17T14:59:23ZengEDP SciencesBIO Web of Conferences2117-44582024-01-01840302810.1051/bioconf/20248403028bioconf_aquaculture2024_03028Application of genetically engineered biopharmaceutical products in children with various JIA forms in the Karaganda regionKenzhetaeva Tattigul0Serikova Gulmira1Alimshaikhina Kulzhazira2Issayeva Aiman3Sabiyeva Makpal4Sarmankulova Gulmira5Medical University of Karaganda N-C JSCMedical University of Karaganda N-C JSCMedical University of Karaganda N-C JSCMedical University of Karaganda N-C JSCMedical University of Karaganda N-C JSCMedical University of Karaganda N-C JSCThe article presents the experience of using biopharmaceutical products for the treatment of children with juvenile idiopathic arthritis in the cardio-rheumatological department of the PSE “Children’s Hospital of Karaganda” for the period from January 1, 2013, to December 31, 2017. The study included 46 patients with JIA who were on genetically engineered biological therapy (girls 28-60.8%, boys 18-39.1%). Among all patients, 12 (26.1%) suffered from the oligoarticular variant of juvenile idiopathic arthritis with (JIA), 15 (32.6%) – from polyarticular seronegative variant (JIA), 14 (30.4%) – from systemic form (JIA), and 5 (10.9%) from other variants. Adalimumab was used in 24 patients (50.2%). Tocilizumab in 17 (30%) ones, 14 of which had a systemic variant of JIA. Infliximab was applied for 5 patients (10.8%).https://www.bio-conferences.org/articles/bioconf/pdf/2024/03/bioconf_aquaculture2024_03028.pdfjuvenile idiopathic arthritisgenetically engineered biological drugsanti-tnf drugsanti-interleukin-6 drugs |
| spellingShingle | Kenzhetaeva Tattigul Serikova Gulmira Alimshaikhina Kulzhazira Issayeva Aiman Sabiyeva Makpal Sarmankulova Gulmira Application of genetically engineered biopharmaceutical products in children with various JIA forms in the Karaganda region BIO Web of Conferences juvenile idiopathic arthritis genetically engineered biological drugs anti-tnf drugs anti-interleukin-6 drugs |
| title | Application of genetically engineered biopharmaceutical products in children with various JIA forms in the Karaganda region |
| title_full | Application of genetically engineered biopharmaceutical products in children with various JIA forms in the Karaganda region |
| title_fullStr | Application of genetically engineered biopharmaceutical products in children with various JIA forms in the Karaganda region |
| title_full_unstemmed | Application of genetically engineered biopharmaceutical products in children with various JIA forms in the Karaganda region |
| title_short | Application of genetically engineered biopharmaceutical products in children with various JIA forms in the Karaganda region |
| title_sort | application of genetically engineered biopharmaceutical products in children with various jia forms in the karaganda region |
| topic | juvenile idiopathic arthritis genetically engineered biological drugs anti-tnf drugs anti-interleukin-6 drugs |
| url | https://www.bio-conferences.org/articles/bioconf/pdf/2024/03/bioconf_aquaculture2024_03028.pdf |
| work_keys_str_mv | AT kenzhetaevatattigul applicationofgeneticallyengineeredbiopharmaceuticalproductsinchildrenwithvariousjiaformsinthekaragandaregion AT serikovagulmira applicationofgeneticallyengineeredbiopharmaceuticalproductsinchildrenwithvariousjiaformsinthekaragandaregion AT alimshaikhinakulzhazira applicationofgeneticallyengineeredbiopharmaceuticalproductsinchildrenwithvariousjiaformsinthekaragandaregion AT issayevaaiman applicationofgeneticallyengineeredbiopharmaceuticalproductsinchildrenwithvariousjiaformsinthekaragandaregion AT sabiyevamakpal applicationofgeneticallyengineeredbiopharmaceuticalproductsinchildrenwithvariousjiaformsinthekaragandaregion AT sarmankulovagulmira applicationofgeneticallyengineeredbiopharmaceuticalproductsinchildrenwithvariousjiaformsinthekaragandaregion |